Boston Scientific Corporation (NYSE:BSX) has been the object of insider selling activity recently. EVP Daniel J. Brennan sold 92,158 shares at an average price of $27.48 on July 11th. The EVP now owns $5,907,101 of the stock as reported to the SEC. David A. Pierce, Sr VP sold $379,736 worth of shares at an average price of $28.00 on Fri the 9th. Pierce now owns $677,628 of stock per an SEC filing yesterday.
Timothy A. Pratt, EVP disclosed the sale of 10,000 shares of BSX stock. The shares were purchased at an average price of $27.13. Pratt now owns $5,855,902 of the stock per the Form 4 SEC filing.
Boston Scientific Corporation, launched on June 22, 1979, is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: interventional cardiology, cardiac rhythm management, endoscopy, peripheral interventions, urology and pelvic health, neuromodulation, and electrophysiology. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. It sells ACURATE TA and ACURATE neo /TF valve systems in Europe and in other geographies outside of the United States..
Here are some other firms who have updated their holdings. As of quarter end Gateway Investment Advisers LLC had acquired a total of 96,639 shares growing its stake by 8.4%. The value of the company’s investment in Boston Scientific Corporation increased from $28,686,000 to $34,652,000 a change of 20.8% since the last quarter. Churchill Management Corp trimmed its position by shedding 2,296 shares a decrease of 1.6% in the quarter. Churchill Management Corp controls 140,633 shares worth $3,898,000. The value of the position overall is up by 9.6%.
Creative Planning augmented its holdings by buying 2,234 shares an increase of 5.5% as of 06/30/2017. Creative Planning now controls 42,540 shares with a value of $1,179,000. The total value of its holdings increased 17.7%. Clinton Group Inc reduced its ownership by shedding 41,025 shares a decrease of 65.3%. Clinton Group Inc owns 21,789 shares valued at $541,000. The value of the position overall is down by 60.2%.
On October 6 Citigroup made no change to the company rating of “Buy” and raised the price expectation to $29.00 from $23.00. On September 1 the company was upgraded from “” to “Buy” and a price target of $33.00 was set in a report issued by Argus Research.
On July 29 JP Morgan kept the stock rating at “Hold” and raised the price target to $24.00 from $18.00. On June 9 analysts at Guggenheim Securities started coverage setting a rating of “Buy”.
On May 23 the stock rating was downgraded to “Neutral” from “” by BTIG Research. Nomura added the stock to its research portfolio with a rating of “Buy” and establishing a price target of $22.00.
The company is now up since yesterday’s close of $27.53. Shares of the company are trading at $27.82 which is marginally over $27.37, the 50 day moving average and which is marginally higher than the 200 day moving average of $25.02. The 50 day moving average was up by +1.65% and the 200 day average was up $2.80.
The most current P/E ratio is 89.17 and the market cap of the company is 38.10B. As of the latest earnings report the EPS was $0.31 and is estimated to be $1.25 for the current year with 1,369,401,000 shares currently outstanding. Next quarter’s EPS is expected be $0.31 with next year’s EPS projected to be $1.39.